Ĭonclusion: S/V did not reduce cardiovascular death or hospitalization for heart failure when compared with valsartan in patients with HFpEF.
However, this benefit could not be demonstrated in men. When evaluated in terms of gender differences, S/V was found to provide a significant reduction in primary outcomes in women. Worsening renal function was observed in 1.4% in the S/V group and 2.7% in the valsartan group (p < 0.05). It was observed that the improvement in NYHA symptom classification, which is one of the secondary outcomes, was significantly higher in the S/V group (p < 0.05). Results: The primary endpoint of the study, cardiovascular death or hospitalization rates for heart failure, was similar between the two groups. Patients were randomized to either S/V (n = 2,419) versus valsartan (n = 2,403). Method: Patients aged ≥50 years with NYHA class II-IV symptoms, ejection fraction ≥45%, elevated natriuretic peptide levels, and structural heart disease (left atrial enlargement or left ventricular hypertrophy) were enrolled to the study.
Objective : In PARAGON-HF study, it was aimed to evaluate the efficacy and safety of S/V in patients with HFpEF. The efficacy of S/V in patients with HFpEF was evaluated in PARAGON-HF study. Sacubitril–valsartan (S/V) has been shown to provide significant improvement in clinical outcomes in patients with HFrEF. Treatment options that can improve clinical outcomes in these patients are not as much as in low ejection fraction heart failure (HFrEF). Trial: Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction - PARAGON-HFīackground : Heart failure with preserved ejection fraction (HFpEF) can lead to significant morbidity and mortality. Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction - PARAGON-HF Türk Kardiyoloji Derneği Genç Kardiyologlar Bülteni - Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction - PARAGON-HF (Dr. Turkish Society of Cardiology Young Cardiologists Bulletin Year: 4 Number: 1 / 2021
0 kommentar(er)
